These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 34484992)
1. Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan. Habu Y; Hamasaki R; Maruo M; Nakagawa T; Aono Y; Hachimine D J Gen Fam Med; 2021 Sep; 22(5):237-245. PubMed ID: 34484992 [TBL] [Abstract][Full Text] [Related]
2. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan. Habu Y Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China. Wang Z; Sun R; Sheng Y; Qu S; Dong L; Wu B Ann Transl Med; 2022 Apr; 10(8):480. PubMed ID: 35571388 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux. Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M Digestion; 2020; 101(2):174-183. PubMed ID: 30897577 [TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis. Zhuang Q; Chen S; Zhou X; Jia X; Zhang M; Tan N; Chen F; Zhang Z; Hu J; Xiao Y Am J Gastroenterol; 2024 May; 119(5):803-813. PubMed ID: 38345252 [TBL] [Abstract][Full Text] [Related]
6. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis. Iwakiri K J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181 [TBL] [Abstract][Full Text] [Related]
7. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y Digestion; 2017; 95(4):281-287. PubMed ID: 28501868 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors. Mizuno H; Yamada K; Minouchi K; Kamiyamamoto S; Hinoue Y Biomed Rep; 2018 Feb; 8(2):148-155. PubMed ID: 29435273 [TBL] [Abstract][Full Text] [Related]
10. The role of vonoprazan in patients with erosive esophagitis. Zhang M; Xiao Y; Chen M Therap Adv Gastroenterol; 2022; 15():17562848221122623. PubMed ID: 36117573 [TBL] [Abstract][Full Text] [Related]
11. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease. Abe Y; Koike T; Saito M; Okata T; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Masamune A Digestion; 2021; 102(3):480-488. PubMed ID: 32062650 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease. Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102 [TBL] [Abstract][Full Text] [Related]
13. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis. Shirai Y; Kawami N; Iwakiri K; Kuwana M J Scleroderma Relat Disord; 2022 Feb; 7(1):57-61. PubMed ID: 35386943 [TBL] [Abstract][Full Text] [Related]
14. Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor: A Pilot Study on Comparable Efficacy in the Treatment of Gastroesophageal Reflux-Related Cough. Zhong S; Zhong M; Fang L; Zhi H; Ji X; Tang K; Zhan C; Shi X; Xian M; Wang W; Li J; Luo W; Lai K; Chen R Allergy Asthma Immunol Res; 2024 Mar; 16(2):191-201. PubMed ID: 38528386 [TBL] [Abstract][Full Text] [Related]
15. Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan. Yamamichi N; Shimamoto T; Takahashi Y; Takahashi M; Takeuchi C; Wada R; Fujishiro M PLoS One; 2022; 17(6):e0270252. PubMed ID: 35714110 [TBL] [Abstract][Full Text] [Related]
16. Health Care Cost Analysis of PPI or P-CAB-First Treatment in Patients With Gastroesophageal Reflux Disease. Miwa H; Shiotani A; Takeda M; Eda M; Kato T; Yajima T J Clin Gastroenterol; 2023 Apr; 57(4):370-379. PubMed ID: 35316226 [TBL] [Abstract][Full Text] [Related]